Shares in Verve Therapeutics ( VERV -0.54%) soared 80.5% this week on the news of an agreement for Eli Lilly ( LLY -2.54%) to ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including Lilly's newest acquisition, ...

Accenture PLC (ACN) is expected to report $3.32 for 3Q. CarMax Inc (KMX) is expected to report $1.19 for 1Q. Coffee Holding Co Inc (JVA) is expected to report $0.06 for 2Q. Darden Restaurants Inc (DRI ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Deal would add a potential treatment for cardiovascular disease to Eli Lilly’s portfolio.

Solar stocks tumbled after Senate Republicans maintained a full phase-out of [solar and wind-energy tax credits]( ...

Specialist Consultant Paediatrician and Honorary Senior Fellow, Postgraduate Institute of Medicine, University of Colombo, ...

Boston-based Verve is a rare example of a gene-editing company targeting a disease that affects a large population, offering ...

With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of Verve’s one-time treatments are in the clinic. Lead ...